Century Therapeutics, Inc.
About Century Therapeutics, Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $109.2M
- Net income
- -$9.6M
- Total assets
- $223.7M
- Market cap
- $384.2M
- Operating margin
- -15.8%
- Net margin
- -8.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $109.2M
- Operating expenses
- $126.4M
- Operating income
- -$17.3M
- Income tax
- -$68.0K
- Net income
- -$9.6M
- EPS (basic)
- $-0.14
- EPS (diluted)
- $-0.14
Balance sheet
- Total assets
- $223.7M
- Current assets
- $120.8M
- Total liabilities
- $64.8M
- Current liabilities
- $20.2M
- Shareholders’ equity
- $158.9M
Cash flow
- Operating cash flow
- -$103.9M
- Investing cash flow
- $107.5M
- Financing cash flow
- $173.0K
- Net cash flow
- $3.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $384.2M
- EPS (diluted)
- $-0.14
- Shares outstanding
- 181.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.6M in FY2025.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Century Therapeutics, Inc..
Write a review
News about Century Therapeutics, Inc.
News & sentiment via Polygon.io
